Response to neo-adjuvant chemotherapy for colorectal liver metastasis of cancer: a key to improving the survival?

R. Bertani Chiappa, e., r. Biffi, u. peace

Liver Resection in colorectal cancer metastatic disease offers the best chance in cases selected for the long-term survival. Intravenous pyelogram (NACT) Chemotherapy was supported in some cases initially deemed irresectable, with few reports the effectiveness of this strategy and the influence of chemoresponsiveness on the outcome of radical liver resection. Methodology: Between December 1995 and 27 patients with colorectal liver metastases, May 2005 (7 20 females, males, mean age: 58 8 years; range: 40-75) were treated with chemotherapy neoadjuvant chemotherapy.You performed a survival analysis of 7 years. Chemotherapy included mainly 5-fluorouracil, leucovorin and Oxaliplatin and irinotecan to a median of 8 courses.

Sixteen patients (59%) had synchronous and 11 metastasis metachronous (41%). during the regression of cancer chemotherapy pre that occurred in 10 cases (37%); stable disease (SD) in a further 10 patients (37%) and the progressive disease (PD) developed in 7 cases (26%). Year 5 General survival for NACT responders was 64% and only 15% for non-responders (p = 0.044).

The response to chemotherapy is likely to be a significant prognostic factor affecting the survival after liver resection for care.

Volume: 1 article number: 58 DOI: 10.3332/ecancer. 2008 58 received: 20/08/2007 published: 16/10/2007

To view this article in its entirety, you must first sign in or register.

View the original article here

Azacitidine extends overall survival and reduces infections and admissions in patients with acute myeloid leukemia WHO defined than the conventional ancillary care: update

P. Fenaux, g. j. Mufti, e. Hellström-Lindberg, v. Santini, n. Gattermann, g. Sanz, a. f. list, s. d. Gore, j. f. Seymour, j. Backstrom, l. Zimmerman McKenzie, d., c. l. Beach l. b. Silverman

AZA (Azacitidine) as demonstrated in phase III trial (AZA-001), is the first treatment MDS prolong significantly overall survival (OS) in high risk patients (pts) MDS (Blood 2007; 110: 817).About one third of pts AZA-001 subscribers were FAB RAEB-T (= 20%-30% blasts) and now meet the criteria of WHO for acute myeloid leukemia (AML) (Blood 1999; 17: 3835) recital prognosis (median survival

Volume: 2 article number: 121 DOI: 10.3332/ecancer. 2008.121 received: 01/11/2008 published: 10/12/2008

To view this article in its entirety, you must first sign in or register.

View the original article here

Comparative analysis of survival of breast cancer microarray study identifies important predictive genetic journey

About 12% of women in the United States will develop breast cancer in their lifetime. Despite the fact that there have been advances in treatment, including therapy and chemotherapy, breast cancer remains the second most deadly types of cancer in women. Thus, there is a clear need for improved prediction of prognosis of breast cancer for every patient. With the advent of large genetic databases and reduce costs for experiments researchers are faced with choices from a large number of potential prognostic markers of breast Cancer gene expression numerous profile study.

Five microarray data sets associated with breast cancer were examined using a set of gene analysis and crayfish have been grouped under different subtypes, using a scoring system based on genetic path.

We note that significant genes in separate studies show a little reproducibility between datasets.From our comparative analysis using gene pathways clinical variables is more reliable and promising research to assess patient prognosis.

The study concluded that in light of clinical variables, there are significant gene pathways between datasets in particular several paths you can considerably further stratify patients survival. Pathways to help develop these candidates has a large group of biomarkers for prognosis of breast cancer patients in the clinical setting.

View the original article here